肠道菌群与酒精性和非酒精性脂肪性肝病的新进展。
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
机构信息
Department of Pediatrics, University of California San Diego, La Jolla, California.
Department of Medicine, University of California San Diego, La Jolla, California.
出版信息
Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.
Abstract
Alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are important causes of morbidity and mortality worldwide. The intestinal microbiota is involved in the development and progression of both ALD and NAFLD. Here we describe associated changes in the intestinal microbiota, and we detail randomized clinical trials in ALD and NAFLD which evaluate treatments modulating the intestinal microbiome including fecal microbiota transplantation, probiotics, prebiotics, synbiotics, and antibiotics. Finally, we discuss precision medicine approaches targeting the intestinal microbiome to ameliorate ALD and NAFLD.
摘要
酒精性肝病 (ALD) 和非酒精性脂肪性肝病 (NAFLD) 是全球发病率和死亡率的重要原因。肠道微生物群参与了 ALD 和 NAFLD 的发展和进展。在这里，我们描述了肠道微生物群的相关变化，并详细介绍了评估调节肠道微生物组的治疗方法的随机临床试验，包括粪便微生物群移植、益生菌、益生元、合生菌和抗生素。最后，我们讨论了针对肠道微生物组的精准医学方法，以改善 ALD 和 NAFLD。
相似文献
1
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.肠道菌群与酒精性和非酒精性脂肪性肝病的新进展。
Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.
2
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.综述文章：细菌可以成为药物吗？益生菌和益生元作为非酒精性脂肪性肝病治疗手段的潜力。
Aliment Pharmacol Ther. 2019 Sep;50(6):628-639. doi: 10.1111/apt.15416. Epub 2019 Aug 2.
3
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群：非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
4
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.肠道微生物群作为治疗非酒精性脂肪性肝病和酒精性肝病的治疗靶点。
Biomed Pharmacother. 2021 Mar;135:111235. doi: 10.1016/j.biopha.2021.111235. Epub 2021 Feb 6.
5
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.调控非酒精性脂肪性肝病的肠道微生物组：益生菌、益生元、合生元和抗生素。
J Microbiol. 2018 Dec;56(12):855-867. doi: 10.1007/s12275-018-8346-2. Epub 2018 Oct 25.
6
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.肠道微生物组与非酒精性脂肪性肝病：分子见解与治疗展望。
J Gastroenterol. 2020 Feb;55(2):142-158. doi: 10.1007/s00535-019-01649-8. Epub 2019 Dec 16.
7
Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.益生菌、益生元和合生元在非酒精性脂肪性肝病和酒精相关性肝病中的作用。
Am J Physiol Gastrointest Liver Physiol. 2023 Jul 1;325(1):G42-G61. doi: 10.1152/ajpgi.00017.2023. Epub 2023 May 2.
8
Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).用营养干预、益生菌、合生菌和粪便微生物群移植（FMT）来对抗脂肪肝疾病。
Adv Exp Med Biol. 2019;1125:85-100. doi: 10.1007/5584_2018_318.
9
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.通过调节肠道微生物群实现酒精性和非酒精性脂肪性肝病的精准医学
Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1018-G1036. doi: 10.1152/ajpgi.00245.2016. Epub 2016 Sep 29.
10
Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.非酒精性脂肪性肝病的肠道微生物组靶向治疗：系统评价、荟萃分析和荟萃回归。
Am J Clin Nutr. 2019 Jul 1;110(1):139-149. doi: 10.1093/ajcn/nqz042.
引用本文的文献
1
Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases.肠道微生物群对肝脏和肠道疾病中肠道通透性的影响。
Microorganisms. 2025 May 23;13(6):1188. doi: 10.3390/microorganisms13061188.
2
The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases.短链脂肪酸在代谢功能障碍相关脂肪性肝病及其他代谢性疾病中的作用
Biomolecules. 2025 Mar 22;15(4):469. doi: 10.3390/biom15040469.
3
Is Associated with Disease Severity in MASLD but Its Supplementation Does Not Improve Diet-Induced Steatohepatitis in Mice.与非酒精性脂肪性肝病（MASLD）的疾病严重程度相关，但补充该物质并不能改善小鼠饮食诱导的脂肪性肝炎。
Microorganisms. 2025 Mar 18;13(3):675. doi: 10.3390/microorganisms13030675.
4
Food for thought: Making the case for food produced via regenerative agriculture in the battle against non-communicable chronic diseases (NCDs).值得思考的问题：在对抗非传染性慢性病（NCDs）的斗争中，论证通过再生农业生产的食物的合理性。
One Health. 2024 Apr 20;18:100734. doi: 10.1016/j.onehlt.2024.100734. eCollection 2024 Jun.
5
Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.真菌特征可将酒精性肝病与非酒精性脂肪性肝病区分开来。
Gut Microbes. 2024 Jan-Dec;16(1):2307586. doi: 10.1080/19490976.2024.2307586. Epub 2024 Feb 1.
6
Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD).利用食物来源的β-葡聚糖预防和治疗非酒精性脂肪性肝病（NAFLD）。
Foods. 2023 Sep 1;12(17):3279. doi: 10.3390/foods12173279.
7
Fecal cytolysin does not predict disease severity in acutely decompensated cirrhosis and acute-on-chronic liver failure.粪便细胞毒素不能预测急性失代偿性肝硬化和慢加急性肝衰竭的疾病严重程度。
Hepatobiliary Pancreat Dis Int. 2023 Oct;22(5):474-481. doi: 10.1016/j.hbpd.2023.05.003. Epub 2023 May 9.
8
Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.益生菌、益生元和合生元在非酒精性脂肪性肝病和酒精相关性肝病中的作用。
Am J Physiol Gastrointest Liver Physiol. 2023 Jul 1;325(1):G42-G61. doi: 10.1152/ajpgi.00017.2023. Epub 2023 May 2.
9
Liver cirrhosis and immune dysfunction.肝硬化和免疫功能障碍。
Int Immunol. 2022 Sep 6;34(9):455-466. doi: 10.1093/intimm/dxac030.
本文引用的文献
1
Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial.粪菌移植改善肥胖患者代谢：FMT-TRIM 双盲安慰剂对照先导试验。
PLoS Med. 2020 Mar 9;17(3):e1003051. doi: 10.1371/journal.pmed.1003051. eCollection 2020 Mar.
2
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.2020年非酒精性脂肪性肝病：疾病现状
Gastroenterology. 2020 May;158(7):1851-1864. doi: 10.1053/j.gastro.2020.01.052. Epub 2020 Feb 13.
3
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.共生元改变粪便微生物组，但不能改变非酒精性脂肪性肝病患者的肝脏脂肪或纤维化：一项随机试验。
Gastroenterology. 2020 May;158(6):1597-1610.e7. doi: 10.1053/j.gastro.2020.01.031. Epub 2020 Jan 25.
4
Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis.细胞溶素阳性粪肠球菌在非酒精性脂肪性肝炎患者中并未增加。
Liver Int. 2020 Apr;40(4):860-865. doi: 10.1111/liv.14377. Epub 2020 Jan 23.
5
Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease.系统评价与Meta分析：益生菌在非酒精性脂肪性肝病中的作用
Gastroenterol Res Pract. 2019 Dec 11;2019:1484598. doi: 10.1155/2019/1484598. eCollection 2019.
6
Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis.微生物功能变化与肝硬化胶囊粪便移植后的临床结果相关。
JCI Insight. 2019 Dec 19;4(24):133410. doi: 10.1172/jci.insight.133410.
7
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.噬菌体靶向肠道细菌可减轻酒精性肝病。
Nature. 2019 Nov;575(7783):505-511. doi: 10.1038/s41586-019-1742-x. Epub 2019 Nov 13.
8
The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.白色念珠菌外毒素白念珠菌溶素促进酒精相关性肝病。
J Hepatol. 2020 Mar;72(3):391-400. doi: 10.1016/j.jhep.2019.09.029. Epub 2019 Oct 10.
9
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis.益生菌对非酒精性脂肪性肝病的影响：一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2019 Sep 25;12:1756284819878046. doi: 10.1177/1756284819878046. eCollection 2019.
10
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae.由高产酒精的肺炎克雷伯菌引起的脂肪肝疾病。
Cell Metab. 2019 Oct 1;30(4):675-688.e7. doi: 10.1016/j.cmet.2019.08.018. Epub 2019 Sep 19.
Zotero 插件